| Group 1 | Group 2 | Group 3 |
---|---|---|---|
No. of revisions (and patients) | 62 (61) | 6 | 4 |
Arthroplasties (no.) | THA 29; TKA 33 | THA 3; TKA 3 | THA 3; TKA1 |
Prosthesis age, years (median, interquartile range (0.25–0.75)) | 9.2 (2.7–15.8) | 11.8 (3.1–19.9) | 7.6 (5.5–9.2) |
Prior antibiotic treatment (no.) | 3 | 0 | 0 |
CRP (μg/mL, (median, interquartile range (0.25–0.75)) | 7.4 (1.5–8.5)c | 6.5 (1–2.5)c | 28.2 (20.3–39.5)c |
WBC (range 109/L, (median, interquartile range (0.25–0.75)) | 7.2 (6.1–8.4) | 5.9 (3.9–6.8) | 7.5 (6.4–9.1) |
Number of positive periprosthetic synovial tissue biopsies (a set comprises 5 biopsies) | 0 | 1–2 | 3–5 |
Reclassification based on work-up of standard tissue samples | |||
Aseptic failure | 61 | 4 | 0 |
Prosthetic joint infection | 0 | 1a | 4a |
Indeterminable | 1a | 1a | 0 |
Project diagnostics, culture (Cul) and molecular (Mol), number of cases | |||
Joint fluid | Cul 2 Mol 1 | Cul 2 Mol 0 | Cul 3 Mol 1 |
Sonication fluid | Cul 2 Mol 0 | Cul 1 Mol 1 | Cul 3 Mol 3 |
Bone biopsy | Cul 0 Mol 2 | ─ | Cul 1 Mol 0 |
Swab from prosthetic element | Cul 1 Mol 3 | ─ | Cul 2 Mol 1 |
Follow-up period, days (median & range) | 396 (3b-1097) | 367 (47–1131) | 363 (96–1051) |
Indication for revision during follow-up | |||
Aseptic failure | 4 | 0 | 0 |
Prosthetic joint infection | 1 | 0 | 0 |